1. Background {#sec1}
=============

Approximately 3.7%--7.5% of the total number of breast cancer patients diagnosed each year in the US \[[@B1], [@B2]\] and Western Europe \[[@B3]--[@B5]\] are younger than 40 years. In Saudi Arabia, the proportion of breast cancer patients ≤40 years at diagnosis is dramatically larger with 25.1% \[[@B6]\].

Multiple retrospective series and subset analyses of larger randomized trials have shown that young patients with breast cancer have a poorer prognosis \[[@B7]--[@B16]\] compared to older age at diagnosis. Breast cancer patients ≤40 years tend to have more triple-negative and fewer luminal A and B breast cancers \[[@B17]--[@B19]\], tumors of higher grade, more extensive intraductal component, more lymphovascular invasion, more likely estrogen receptor- (ER-) negative tumors \[[@B20]--[@B23]\], and more often BRCA-1 or -2 germline mutations \[[@B13], [@B24]--[@B27]\]. Although young women do appear to have tumors with more aggressive biological characteristics, younger age has been shown in several studies to be an independent predictor of adverse outcome \[[@B18], [@B20], [@B22], [@B28]--[@B31]\]. Several current consensus guidelines have included age ≤35 years as an absolute indication for adjuvant systemic chemotherapy irrespective of other tumor characteristics \[[@B32]--[@B35]\]. More research is needed to optimize the treatment for this patient group \[[@B14], [@B36], [@B37]\]. Detailed data about prognostic factors and treatment outcome in breast cancer are scarce in Saudi Arabia and the Middle East. The purpose of this study was to characterize the breast cancer patients treated with curative intend of this tertiary care hospital in Saudi Arabia ≤40 years of age at diagnosis compared to \>40 years, and to assess their prognosis.

2. Methods {#sec2}
==========

Medical records were retrospectively reviewed of female breast cancer patients who consulted Saad Specialist Hospital between 2004 and 2011. Eligibility criteria for the analysis were histologically confirmed diagnosis of invasive breast cancer or cancer in situ, surgical treatment with breast conserving surgery or mastectomy with curative intent. Patients with distant metastases, synchronous, or metachronous cancer at diagnosis were excluded from the analysis.

Staging procedures included complete history and physical examination, laboratory assessments, and diagnostic bilateral mammogram. Where indicated, ultrasonography of the breast and abdomen, chest radiograph, and radionuclide bone scan were performed. Selected patients received magnetic resonance imaging (MRI) of the breast, computerized tomography (CT), or positron emission tomography-computed tomography (PET-CT). Patients were presented and discussed in an interdisciplinary Tumor Board Meeting, and a treatment recommendation was generated usually based on the guidelines of the National Comprehensive Cancer Network (NCCN).

Breast conserving surgery (BCS) consisted of wide local excision or lumpectomy and axillary dissection or sentinel lymph node biopsy in selected patients. After modified radical mastectomy, in selected patients breast reconstruction with TRAM-flap or latissimus dorsi-flap was performed. Surgery was followed by chemotherapy and hormonal therapy where indicated. Dependent on the T status, N status, hormone receptor status, age (≤35 years versus \>35 years), and menopausal status, four cycles of Adriamycin/Cyclophosphamide (AC) or six cycles of Cyclophosphamide/Methotrexate/5-FU (CMF) were prescribed for node-negative patients, and four cycles of AC followed by four cycles of paclitaxel or, alternatively, three cycles of 5-FU/Epirubicin/Cyclophosphamide (FEC) followed by three cycles of docetaxel for node positive patients. Endocrine therapy using tamoxifen or aromatase inhibitors was prescribed where indicated. Herceptin was added according to the Her2neu status and prescribed for at least one year. Triple negative patients were usually treated with four cycles of AC followed by four cycles of paclitaxel. In selected patients neoadjuvant chemotherapy was applied.

Postoperative radiotherapy was performed in all patients after BCS. A total dose of 50.4 Gy in 28 fractions was prescribed, followed by a boost of 10 Gy in 5 fractions in all patients younger than 50 years. Postmastectomy radiotherapy of the chest wall was given in patients with at least one positive locoregional lymph node. The prescribed dose was 50 Gy in 25 fractions. Usually three-dimensional conformal radiotherapy (3D-CRT) using opposed tangential beam was applied for the treatment of the whole breast or the chest wall. In selected patients, intensity modulated radiotherapy (IMRT) was used to reduce the dose volume of the heart and lung \[[@B38]\].

Follow-up examinations were scheduled every three months in the first year, then every six months for 4 years.

Breast cancer was classified according to the International Union Against Cancer (UICC), with group clinical and pathological staging according to the American Joint Committee on Cancer (AJCC, 6th edition).

Data were entered into a computerized database (MS Access 2010) and analysed using a statistical software package (SPSS 19).

2.1. Immunohistochemistry {#sec2.1}
-------------------------

Sections with a thickness of four *μ*m were cut from paraffin blocks and used for immunohistochemical staining using the iVIEW DAB detection kit on BenchMark autostainer (Ventana, Tucson, AZ, USA). The clones of antibodies SP1, 1E2, and 4B5 were used to evaluate the ER-a, PR, and Her2neu status. The Allred scoring system was used to assess the ER and PR status \[[@B39]\]. In summary, a total Allred score was obtained by the summation of proportion score (PS) and intensity score (IS). PS is assigned depending on the proportion of positive cells (0 = none; 1 \<1%; 2 = 1% -\<1/10; 3 = 1/10 -\<1/3; 4 = 1/3 -\<2/3; 5 ≥2/3), IS (0 = none; 1 = weak; 2 = intermediate; 3 = strong). A total score of 2 or more was considered as positive; scores 0 and 1 were considered negative.

The American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guideline recommendations were used to evaluate the Her2neu status \[[@B40]\]. Briefly, score 0 indicates no staining in invasive tumor cells. Score +1 indicates weak incomplete membrane staining in any proportion of invasive tumor cells or weak complete membrane staining in \<10% of cells. Score +2 indicates complete membrane staining in nonuniform or weak but with obvious circumferential distribution in ≥10% of cells, or intense complete membrane staining in ≤30% of tumor cells. Score +3 indicates uniform intense membrane staining of \>30% of invasive tumor cells. Scores 0 and +1 were considered negative; +2 equivocal; and +3 positive.

Gene expression profiling studies have shown that immunohistochemistry of paraffin sections is a reliable surrogate for molecular classification of invasive breast cancers \[[@B41]--[@B46]\]. Based on this finding, patients of this study were categorized as follows: luminal A (ER+, PR+, Her2neu−), luminal B (ER+ and/or PR+, Her2neu+), Her2neu overexpressing (ER−, PR−, Her2neu+), and triple negative (ER−, PR−, Her2neu−).

2.2. Statistical Analysis {#sec2.2}
-------------------------

The *Z*-test was used to test for statistically significant different proportions concerning disease- and treatment-related factors of patients ≤40 years versus \>40 years.

The locoregional failure-free survival was estimated using the Kaplan-Meier method, and patient groups were compared using the log rank test. The locoregional failure-free survival was defined as the time between diagnosis and locoregional failure or death of any cause. Patients who have not experienced a locoregional failure were censored at the time of their last follow-up. The simultaneous relationship of multiple prognostic factors to locoregional failure was assessed using Cox\'s proportional hazard regression analysis. The regression coefficients were estimated by the maximum likelihood method, and model selection was performed by a stepwise strategy using the likelihood ratio test. A 5% significance level was used and all tests are two-sided. No correction for multiple testing was used.

3. Results {#sec3}
==========

The proportion of patients ≤40 years of all breast cancer patients who consulted Saad Specialist Hospital was 22.6%, which is very much in accordance to the proportion of breast cancer patients ≤40 years published by the Cancer Incidence and Survival Report Saudi Arabia 2007 of 25.1% \[[@B6]\]. Two hundred and thirteen of all breast cancer patients met the eligibility criteria of this study and were analysed. Of those, 158 patients were \>40 years of age at diagnosis and 55 patients ≤40 years.

The patient and treatment characteristics are demonstrated in [Table 1](#tab1){ref-type="table"}. The median follow-up time of the censored patients was 22 months (mean 28 months, range 3--92 months).

Patients of ≤40 years at diagnosis exhibited statistically significantly less frequently the tumor type luminal A, and statistically significantly more frequently the tumor type triple negative compared to patients \>40 years ([Table 1](#tab1){ref-type="table"}). In addition, the body mass index (BMI) and the menopausal status were significantly different in the two age groups ([Table 1](#tab1){ref-type="table"}). The mean BMI (standard deviation) of all patients was 31.1 (6.0), of patients ≤40 years 28.3 (5.2), and for patients \>40 years 32.1 (6.0).

On univariate analysis, the age (≤40 versus \>40 years), T stage (Tis, T0--2 versus T3-4), molecular tumor type (luminal A versus luminal B, Her2neu overexpression, triple negative), and lymphovascular status (LV0 versus LV1) had a significant impact on the locoregional failure-free survival ([Table 2](#tab2){ref-type="table"}, Figures [1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}). The N status (N0 versus N+) showed a statistical trend of an association with the locoregional failure-free survival (*P* = 0.13). On multivariate analysis, the age and T stage remained statistically significant ([Table 3](#tab3){ref-type="table"}).

4. Discussion {#sec4}
=============

In Saudi Arabia, the proportion of breast cancer patients ≤40 years of age at diagnosis is about three times larger than generally reported in the West (25.1% versus 3.7%--7.5%). According to the US Census Bureau \[[@B47]\], the proportion of females ≤40 years of the Saudi Arabian population is only 1.5 times larger than that of the US population (80.4% versus 52.2%; year 2010), suggesting that the larger proportion of breast cancer patients ≤40 years in Saudi Arabia may not be fully explained by the different age structures of the two populations. This observation and also the fact that some studies performed in Asia and Africa did not find a different prognosis of younger breast cancer patients compared to the older counterparts \[[@B48], [@B49]\] suggest that regional differences may exist concerning the biology and prognosis of young breast cancer patients. Detailed clinicopathological and prognostic data are scarce in Saudi Arabia and the Middle East.

Our data show that young age is an independent negative prognostic factor for the locoregional control of breast cancer patients in Saudi Arabia. The same finding has been reported by another retrospective single-institutional study in Saudi Arabia \[[@B50]\]. Our findings are compatible with the notion that breast cancer arising in a younger host is a unique entity characterized not only by adverse prognostic features, but also by a diverse underlying biology against which novel therapeutics should be targeted \[[@B1], [@B31]\]. Several current consensus guidelines have included age ≤35 years as an absolute indication for adjuvant systemic chemotherapy irrespective of other tumor characteristics \[[@B32]--[@B35]\]. The observation of a higher locoregional recurrence rate after BCS compared to mastectomy in patients ≤35 years of age in some studies \[[@B20], [@B21], [@B28], [@B51]--[@B56]\] raised the question about the optimal surgical approach of this patient group. However, a recently published large population-based analysis consisting of 1,453 early breast cancer patients ≤40 years showed that the 10-year overall survival was not impaired after BCS compared to mastectomy \[[@B57]\]. In line with this observation, no difference of the two-year locoregional failure-free survival was detected in our study after BCS or mastectomy (*P* = 0.59). A pooled analysis of four EORTC randomized controlled trials revealed that tumor size, nodal status, and molecular tumor subtype were independent prognostic factors for overall survival of the subgroup of young breast cancer patients \[[@B58]\]. The authors concluded that future treatment guidelines concerning young breast cancer patients should be refined based upon tumor characteristics, probably derived from microarray driven translational research projects, and not based upon age alone \[[@B59]--[@B61]\]. In our study, the molecular tumor subtype had a prognostic relevance for all patients on univariate analysis, but lost its significance on multivariate analysis.

Breast cancer in young women is probably the result of a complex interaction between genetic, environmental, and nongenetic patient related factors \[[@B24], [@B25], [@B27], [@B31], [@B62]--[@B68]\]. However, no significant difference of the family history was found between breast cancer patients ≤40 years and \>40 years in our study. A striking difference to representative data from North America or Europe was the significantly higher BMI of our study patients. The mean BMI (standard deviation) of our study population was 31.1 (6.0) compared to 24.8 (4.4) in North America \[[@B69]\]) and 25.5 (4.5) in Europe \[[@B70]\]. A closer look revealed that the main difference was confined to the subgroup of young patients. In our study, the proportion of patients ≤40 years with a BMI of ≤25, 25--30, and \>30 was about 33% for each category, whereas in the western studies the corresponding proportions ranged from 57.0%--73.2%; 19.4%--27.5%, and 12.1%--17.1%, respectively \[[@B71]--[@B75]\]. The differences of the BMI of older patients compared to the West were much smaller (our study: 58.5%, 30.5%, and 11.0%; western studies: 41.6%--52.9%, 28.7--37.5%, and 11.5%--20.9% \[[@B74], [@B75]\]).

Studies have shown that the BMI is associated with poor prognosis in both premenopausal \[[@B72]--[@B74], [@B76], [@B77]\] and postmenopausal patients \[[@B74]--[@B80]\]. In addition, the BMI has been shown to be associated with an increased breast cancer risk in postmenopausal women \[[@B69], [@B70], [@B81]\]. In premenopausal women, a protective or no effect of the BMI on the breast cancer risk has been observed \[[@B70], [@B71], [@B82]--[@B86]\]. In contrast, several studies considering multiple surrogate markers for obesity have also reported an association of obesity with an increased risk to develop breast cancer in premenopausal women \[[@B69], [@B87], [@B88]\]. Although the association between body weight and breast cancer appears to be complex, it represents an interesting factor to be evaluated in future studies concerning breast cancer in Saudi Arabia.

5. Conclusions {#sec5}
==============

Patients ≤40 years exhibited more often triple negative and less frequently luminal A tumors compared to patients \>40 years. However, multivariate analysis revealed age ≤40 years as an independent adverse prognostic factor for the locoregional failure-free survival of breast cancer patients in Saudi Arabia.

The authors declare that they have no conflict of interests.

Z. Bushnag and A. A. Nour participated in the acquisition of data. H. Sweilmeen, E. Fadel, N. Masri, I. Brune-Erber, and V. Rudat participated in the analysis and interpretation of data, and helped to draft the paper. V. Rudat conceived of the study, participated in its design and coordination, and performed the statistical analysis. S. Altuwaijri helped to draft and critically revised the paper. All authors read and approved the final paper.

AC:

:   Adriamycin/cyclophosphamide

BCS:

:   Breast conserving surgery

BMI:

:   Body mass index

CMF:

:   Cyclophosphamide/methotrexate/5-FU

ER:

:   Estrogen receptor

FEC:

:   5-FU/Epirubicin/cyclophosphamide

IS:

:   Intensity score

PR:

:   Progesterone receptor

PS:

:   Proportion score.

![Locoregional failure-free survival of breast cancer patients ≤40 years versus \>40 years of age at diagnosis.](JO2012-370385.001){#fig1}

![Locoregional failure-free survival of breast cancer patients with luminal A type of tumor versus luminal B, Her2neu overexpression, or triple negative.](JO2012-370385.002){#fig2}

###### 

Comparison of clinical and pathological characteristics of patients ≤40 years and \>40 years of age at diagnosis.

  Characteristic                                                           Age (years)   *P* value                
  ------------------------------------------------------------------------ ------------- ----------- ----- ------ -------
  Body mass index                                                                                                 
   \<25                                                                    14            25.5        13    8.2    ≤0.05
   25--29                                                                  14            25.5        36    22.8   n.s.
   ≥30                                                                     14            25.5        69    43.7   ≤0.05
   Unknown                                                                 13            23.6        40    25.3   n.s.
                                                                                                                  
  Menopausal status                                                                                               
   Premenopausal                                                           54            98.2        75    47.5   ≤0.05
   Postmenopausal                                                          1             1.8         86    52.5   ≤0.05
                                                                                                                  
  Family history                                                                                                  
   No cancers in blood relatives                                           23            41.8        57    36.1   n.s.
   Other than breast cancer in at least one blood relative                 1             1.8         4     2.5    n.s.
   Other than breast cancer in at least one first degree relative          6             10.9        8     5.1    n.s.
   Breast cancer or ovarian cancer in at least one blood relative          4             7.3         13    8.2    n.s.
   Breast cancer or ovarian cancer in at least one first degree relative   2             3.6         19    12.0   n.s.
   Unknown                                                                 19            34.5        57    36.1   n.s.
                                                                                                                  
  Histology                                                                                                       
   Invasive ductal                                                         49            89.1        143   90.5   n.s.
   Invasive lobular                                                        2             3.6         12    7.6    n.s.
   DCIS                                                                    3             5.5         3     1.9    n.s.
   LCIS                                                                    1             1.8         0     0      n.a.
                                                                                                                  
  T stage                                                                                                         
   Tis                                                                     4             7.3         3     1.9    n.s.
   T0                                                                      1             1.8         0     0.0    n.a.
   T1                                                                      16            29.1        55    34.8   n.s.
   T2                                                                      22            40.0        59    37.3   n.s.
   T3                                                                      4             7.3         27    17.1   n.s.
   T4                                                                      6             10.9        10    6.3    n.s.
   Tx                                                                      2             3.6         4     2.5    n.s.
                                                                                                                  
  N stage                                                                                                         
   N0                                                                      18            32.7        59    37.3   n.s.
   N1                                                                      17            30.9        46    29.1   n.s.
   N2                                                                      11            20.0        23    14.6   n.s.
   N3                                                                      6             10.9        26    16.5   n.s.
   Nx                                                                      3             5.5         4     2.5    n.s.
                                                                                                                  
  Stage                                                                                                           
   0                                                                       4             7.3         3     1.9    n.s.
   I                                                                       6             10.9        35    22.2   n.s.
   II                                                                      19            34.5        56    35.4   n.s.
   III                                                                     23            41.8        59    37.3   n.s.
   Unknown                                                                 3             5.5         5     3.2    n.s.
  Grading                                                                                                         
   G1                                                                      2             3.6         14    8.9    n.s.
   G2                                                                      17            30.9        47    29.7   n.s.
   G3                                                                      22            40.0        71    44.9   n.s.
   Gx                                                                      14            25.5        26    16.5   n.s.
                                                                                                                  
  Lymphovascular invasion (LV)                                                                                    
   LV0                                                                     17            30.9        50    31.6   n.s.
   LV1                                                                     15            27.3        53    33.5   n.s.
   Unknown                                                                 23            41.8        55    34.8   n.s.
                                                                                                                  
  Type of surgery                                                                                                 
   Breast conserving surgery                                               22            40.0        70    44.3   n.s.
   Mastectomy                                                              33            60.0        88    55.7   n.s.
                                                                                                                  
  Neoadjuvant chemotherapy                                                                                        
   No                                                                      46            83.6        137   86.7   n.s.
   Yes                                                                     9             16.4        21    13.3   n.s.
                                                                                                                  
  Residual tumor (R) status                                                                                       
   R0                                                                      41            74.5        122   77.2   n.s.
   R1                                                                      3             5.5         12    7.6    n.s.
   Unknown                                                                 11            20.0        24    15.2   n.s.
                                                                                                                  
  Estrogen receptor (ER) status                                                                                   
   ER negative                                                             17            30.9        43    27.2   n.s.
   ER positive                                                             33            60.0        106   67.1   n.s.
   Unknown                                                                 5             9.1         9     5.7    n.s.
                                                                                                                  
  Progesterone receptor (PR) status                                                                               
   PR negative                                                             23            41.8        52    32.9   n.s.
   PR positive                                                             27            49.1        97    61.4   n.s.
   Unknown                                                                 5             9.1         9     5.7    n.s.
                                                                                                                  
  Her2neu status                                                                                                  
   Her2neu negative                                                        33            60.0        115   72.8   n.s.
   Her2neu positive                                                        12            21.8        29    18.4   n.s.
   Unknown                                                                 10            18.2        14    8.9    n.s.
                                                                                                                  
  Tumor subtype                                                                                                   
   Luminal A                                                               20            36.4        94    59.5   ≤0.05
   Luminal B                                                               9             16.4        17    10.8   n.s.
   Her2 overexpressing                                                     3             5.5         12    7.6    n.s.
   Triple negative                                                         14            25.5        21    13.3   ≤0.05
   Unknown                                                                 9             16.4        14    8.9    n.s.

###### 

Results of the Kaplan-Meier analysis.

  Factor                  *n*   2-year locoregional failure-free survival   95% CI       *P* value
  ----------------------- ----- ------------------------------------------- ------------ -----------
  Age                                                                                    0.005
   Age ≤40                54    0.86                                        0.75--0.98   
   Age \>40               158   0.98                                        0.95--1.00   
                                                                                         
  Menopausal status                                                                      0.52
   Premenopausal          129   0.99                                        0.97--1.00   
   Postmenopausal         84    0.97                                        0.91--1.00   
                                                                                         
  BMI                                                                                    0.31
   BMI \<30               72    0.95                                        0.88--1.00   
   BMI ≥30                83    0.97                                        0.92--1.00   
                                                                                         
  T stage                                                                                0.03
   Tis, T0--2             159   0.98                                        0.95--1.00   
   T3-4                   47    0.89                                        0.78--1.00   
                                                                                         
  N stage                                                                                0.13
   N0                     77    1.00                                        1.00-1.00    
   N+                     128   0.94                                        0.88--1.00   
                                                                                         
  Grading                                                                                0.27
   G1-2                   80    1.00                                        1.00-1.00    
   G3                     93    0.93                                        0.86--1.00   
                                                                                         
  Tumor subtype                                                                          0.03
   Luminal A              75    0.91                                        0.83--0.99   
   Others\*               114   0.99                                        0.97--1.00   
                                                                                         
  Lymphovascular status                                                                  0.02
   LV0                    67    1.00                                        1.00-1.00    
   LV1                    68    0.90                                        0.79--1.00   
                                                                                         
  Type of surgery                                                                        0.59
   Mastectomy             121   0.96                                        0.91--1.00   
   BCS                    91    0.97                                        0.92--1.00   
                                                                                         
  Residual tumor status                                                                  0.56
   R0                     163   0.97                                        0.93--1.00   
   R1                     15    1.00                                        1.00-1.00    

Abbreviations. BMI: body mass index; \*: luminal B, Her2 overexpressing, or triple negative; BCS: breast conserving surgery; CI: confidence interval.

###### 

Results of Cox proportional hazards regression analysis.

  Variable   *P* value   Estimated relative hazard   95% CI for relative hazard
  ---------- ----------- --------------------------- ----------------------------
  Age        0.01        0.13                        0.03--0.66
  T stage    0.05        4.06                        1.01--16.3
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